Printer Friendly

Pergamum reaches LPLV stage in a Phase I/II trial of LL-37 for hard-to-heal wounds.

M2 PHARMA-April 19, 2013-Pergamum reaches LPLV stage in a Phase I/II trial of LL-37 for hard-to-heal wounds(C)2013 M2 COMMUNICATIONS

Developer of scientific products Karolinska Development AB (STO:KDEV.ST) announced today that biopharmaceutical company Pergamum has reached last-patient-last-visit (LPLV) in a randomised Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers.

According to the company, this clinical trial will allow Pergamum to evaluate a promising new treatment aimed for the segment of advanced wound care products.

Under the double blind multicenter study, 34 patients with venous leg ulcers have been randomised to receive either placebo or one of three different doses of LL-37. The primary objective of the trial, which will be concluded in 2013, is to assess the safety and tolerability of Pergamum's proprietary formulation of the therapeutic peptide LL-37.

Karolinska Development AB is the majority owner of Pergamum.

((Comments on this story may be sent to>PDApril 19, 2013>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 19, 2013
Previous Article:OPKO Health Inc acquires interest in OAO Pharmsynthez of Russia & commercialises OPKO products in Russia and certain Eastern European markets.
Next Article:Abbott to launch the TECNIS Toric intraocular lens for cataract patients in the US following FDA approval.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters